CN104338135B - The regulatory factor of depression and its application - Google Patents
The regulatory factor of depression and its application Download PDFInfo
- Publication number
- CN104338135B CN104338135B CN201310347938.6A CN201310347938A CN104338135B CN 104338135 B CN104338135 B CN 104338135B CN 201310347938 A CN201310347938 A CN 201310347938A CN 104338135 B CN104338135 B CN 104338135B
- Authority
- CN
- China
- Prior art keywords
- camkii
- purposes
- depression
- group
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11017—Ca2+/Calmodulin-dependent protein kinase (2.7.11.17)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/304—Mood disorders, e.g. bipolar, depression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
Abstract
The present invention provides the regulatory factor of depression and its applications.Specifically, the present invention provides β CaMKII inhibitor applies in preparing the drug for preventing and/or treating depression.The present invention's studies have shown that habenular nucleus overexpression β CaMKII (and non-alpha CaMKII) can induce out the core depressive symptom of anhedonia and behavioral despair on the outside.Habenular nucleus lowers the expression of β CaMKII on the outside, and the depressed phenotype of animal can be reversed by reducing its kinase activity or blocking its downstream molecules GluR1 then.
Description
Technical field
This field is related to biotechnology and field of medicaments, particularly, is related to regulatory factor and its application of depression.
Background technology
Major depressive disorder (MDD) is one of mental disease that is most common and most disabling, has the characteristics that, mood is low
It falls, adynamia, it is desperate, it can not experience happy, also referred to as anhedonia (1).The reason of for leading to MDD, now viewpoint
Think, when responding environmental stimuli such as pressure, the nervous activity of specific brain loop is changed.And it is this change be by
Caused by the variation of specific molecular and cellular level.Recently, outside habenular nucleus (LHb), as from limbic forebrain to numerous lists
The core brain area of information is transmitted at amine center, has become the crucial brain region of depression Pathological Physiology and Therapy study.LHb
The mood that neuron is in detestation activates, including pressure, dejected, frightened or expected negative return.It is consistent therewith, neuroimaging
Research has determined that the raising of the habenular nucleus liveness under depressive state.In addition, one recently is the study found that in animal depression
In model, synaptic activity and the output of LHb neuron peak values are all enhanced.However in LHb these aberrant cellular processes molecule
How the stimulation of mechanism and inducing depression such as pressure leads to the generation that these change, and there is still a need for determine.
The correlation factor adjusted there is an urgent need in the art to depression to be prevented and treated to depression and its effect
Mechanism, and develop the drug that can be used for preventing and/or treat depression.
Invention content
It is an object of the invention to provide the active constituents and drug that can be used for preventing and/or treat depression
In the first aspect of the present invention, a kind of purposes of β CaMKII inhibitor is provided, be used to prepare prevention and/or is controlled
Treat the drug of depression.
In another preferred example, the inhibitor is selected from the group:
(i) RNA interfering or its precursor of interference β CaMKII expression;
(ii) the saltant type β CaMKII albumen or its coded sequence that kinase activity declines or loses;
(iii) inhibit the active inhibitor of β CaMKII;
(iv) competitive inhibitor of β CaMKII;
(v) antibody of anti-β CaMKII;
(vi) antagonist of β CaMKII regulation and control AMPAR GluR1 accesses is checked.
In another preferred example, the RNA interfering is β RNAi (SEQ ID NO.:1,5'-
GAGTATGCAGCTAAGATCA-3')。
In another preferred example, the saltant type β CaMKII albumen is the β CaMKII albumen dominant factors, preferably
Ground is β K43R (Wayman GA et al.2011).
In another preferred example, the inhibitor of the β CaMKII includes KN-93, KN-62, AC3-I
(Autocamtide-3Derived Inhibitory Peptide)、Ant-AIP-II(Autocamtide-2Related
Inhibitory Peptide II,Cell-permeable)。
In another preferred example, the component (vi) is the dominant factor of AMPAR GluR1, preferably
GluR1Ct。
In another preferred example, the inhibitor or antagonist include following form:Polynucleotides, polypeptide, expression carry
Body, micromolecular compound, or combinations thereof.
In another preferred example, the expression vector is selected from the group:Viral vectors.
In another preferred example, the β CaMKII inhibitor is additionally operable to prepare the neuron peak electricity for reducing outside habenular nucleus
The drug of the drug of position output and/or the synaptic efficacy of reduction outside habenular nucleus.
In another preferred example, the drug be targeting in the drug of outside habenular nucleus or the drug be to be applied to
The drug of outside habenular nucleus region or near zone.
In the second aspect of the present invention, a kind of pharmaceutical composition that can be used for preventing and/or treat depression, institute are provided
The pharmaceutical composition stated includes:
Pharmaceutically acceptable carrier;With
Effective quantity active constituent, wherein the active constituent is β CaMKII inhibitor or antagonist.
In another preferred example, the active constituent is to α CaMKII substantially unrestraint/antagonisms.
In another preferred example, the active constituent is to δ CaMKII substantially unrestraint/antagonisms.
In another preferred example, the active constituent is to γ CaMKII substantially unrestraint/antagonisms.Another excellent
It selects in example, the active constituent has inhibition/antagonism to γ CaMKII.
In another preferred example, the active constituent selective depression β CaMKII, and to other CaMKII (including α
CaMKII, γ CaMKII and δ CaMKII) free or substantially free of inhibition/antagonism.
In another preferred example, the β CaMKII inhibitor or antagonist are selected from the group:βCaMKII-RNAi、βK43R、
KN-93、KN-62、AC3-I(Autocamtide-3Derived Inhibitory Peptide)、Ant-AIP-II
(Autocamtide-2Related Inhibitory Peptide II,Cell-permeable)。
In another preferred example, the pharmaceutical composition is oral preparation, injection, targeting preparation etc..
In the third aspect of the present invention, provides a kind of β CaMKII albumen or its coded sequence and/or β CaMKII promote
The purposes of agent, it be used to prepare a reagent or composition, and the reagent or composition are for building animal models of depression.
In another preferred example, in the animal models of depression, β CaMKII are high expression.
In another preferred example, in the animal models of depression, β CaMKII are high expression in habenular nucleus on the outside.
In another preferred example, the high expression refers to >=150% (by mRNA level in-site or protein level), preferably >=
200%, more preferably >=200%.
In another preferred example, the upper limit of the high expression (by mRNA level in-site or protein level) is≤2000%, preferably
≤ 1000%, more preferably≤500%.
In the fourth aspect of the present invention, a kind of side screened for preventing and/or treating the potential substance of depression is provided
Method, including step:
(1) tester to be screened is applied to animal models of depression, wherein in the outside of the animal models of depression
β CaMKII are high expression in habenular nucleus;With
(2) related symptoms and/or index of the depression in the animal models of depression are observed, and are carried out with control group
Compare;
Wherein, the related symptoms of depression are significantly improved in the animal models of depression, then it represents that the tester is
It can be used for preventing and/or treat the potential substance of depression.
In another preferred example, the animal model is non-human mammal, such as rodent, rabbit, Primate.
In another preferred example, in step (2), pass through Animal Behavior Science Germicidal efficacy depressive symptom.
In another preferred example, Animal Behavior Science experiment is selected from the group:Xi Ze-zong experiment forces swimming real
It tests, the experiment of sucrose preference, tail-suspention test, novel inhibit feeding experiment.
In another preferred example, the symptom is selected from the group:Xi Ze-zong (being reduced by lever number), abandoning swimming carries
Morning and quiescent time increase, syrup consumption is reduced, struggle is reduced, food rcstriction increases.
In another preferred example, the index includes:The expression of β CaMKII, the activity level of β CaMKII.
In another preferred example, the application (or administration) includes being administered orally.
In another preferred example, the control group includes:Negative control group and/or positive controls.
In another preferred example, the negative control group includes:The control group of tester is not applied;Or apply tester
Same test group before.
In the fifth aspect of the present invention, a kind of side screened for preventing and/or treating the potential substance of depression is provided
Method, including step:
(1) in test group, tester to be detected is added into vitro detection system;With
(2) detect the expression and/or activity of β CaMKII in the vitro detection system of the test group, and with feminine gender
Control group is compared;
Wherein, if compared with adding negative control group, the expression of β CaMKII is remarkably decreased in test group, and/
Or the activity of β CaMKII is remarkably decreased, then it represents that the tester is the potential substance for preventing and/or treating depression.
In another preferred example, the vitro detection system includes cell system;Preferably neuronal cell system;
Preferably outside Habenular Neurons system.
In another preferred example, described to be remarkably decreased finger, compared with negative control, the expression of β CaMKII in test group
Level or activity is the 5-90% of negative control group, preferably 10-60%, more preferably 20-50%.
In another preferred example, the step (2) further includes being compared with positive controls.
In another preferred example, the method further includes following one or more steps:
To the potential substance that previous step filters out, its influence to the membrane part of GluR1 is further tested;
To the potential substance that previous step filters out, it is applied to animal model, observes its influence to symptoms of depression.
In another preferred example, when testing its influence to the membrane part of GluR1, if (or empty with negative control group
White control group) it compares, it is added or is reduced using GluR1 contents in the test group of the tester, then it represents that the tester is pre-
Anti- and/or treatment depression potential substance.
In another preferred example, the GluR1 contents are the GluR1 contents on neuronal cell film.
In the sixth aspect of the present invention, a kind of purposes of GluR1 inhibitor is provided, prevention and/or treatment are used to prepare
The drug of depression.
In another preferred example, the drug is additionally operable to reduce the neuron spike potential output of outside habenular nucleus and cynapse effect
Energy.
In another preferred example, the GluR1 inhibitor is β CaMKII inhibitor.
In another preferred example, the GluR1 inhibitor is the competitive inhibitor of GluR1, including dominant because
Son, preferably GluR1Ct.
In another preferred example, the GluR1 inhibitor is selected from the group:Polynucleotides, polypeptide, expression vector, small point
Sub- compound, or combinations thereof.
In the seventh aspect of the present invention, a kind of method prevented and/or treat depression, including step are provided:To need
The object wanted applies the β CaMKII inhibitor of safe and effective amount.
In another preferred example, the application is to be applied to outside habenular nucleus region.
In the eighth aspect of the present invention, a kind of method of reduction neuron spike potential output and synaptic efficacy, packet are provided
Include step:The β CaMKII inhibitor of safe and effective amount is applied to the object of needs.
In another preferred example, the object is mammal, including rodent (such as rat, mouse), spirit are long dynamic
Object (such as people).
In another preferred example, the application is to be applied to outside habenular nucleus region.
In the ninth aspect of the present invention, a kind of method prevented and/or treat depression, including step are provided:To need
The object wanted applies the GluR1 inhibitor of safe and effective amount.
In another preferred example, the application is to be applied to outside habenular nucleus region.
It should be understood that within the scope of the present invention, above-mentioned each technical characteristic of the invention and have in below (eg embodiment)
It can be combined with each other between each technical characteristic of body description, to form a new or preferred technical solution.As space is limited, exist
This no longer tires out one by one states.
Description of the drawings
Fig. 1 shows the up-regulation of β CaMKII in depression rat LHb.(A) the depression phenotype of cLH rats.Number represents institute
Use size of animal.In LH tests, maximum pressure number is set as 15.(B) the high-throughput quantification albumen based on stable isotope labeling
Matter group tests sketch map.Briefly, unlabelled habenular nucleus (14N) WT or cLH rats are dissected, and homogenize, and with 1:1 ratio
With15The total brain tissue homogenate's mixing of rat of N labels.Membrane part is concentrated, 500g protein examples are used for standard mass spectral analysis.Meter
Calculation has each identified peptide fragment14N/15N ratios.Compare cLH and each protein peptide fragment ratio details of control group look at method portion
Point.(C) proteome analysis that β CaMKII are determined in 3 independent proteomics operations, based on total peptide fragment, or
Unique peptide fragment (being not the peptide fragment common to other members in family).(D, E) Western blot are analysis shows that in cLH rats
Reins (D) or hippocampus (E) membrane part β CaMKII variation.A large amount of tubulins of tissue are used as Loading Control.Protein expression
Carry out quantitative criterion.(F) qPCR of β CaMKII mRNA is analyzed in reins.(G) CaMKII is horizontal in outside habenular nucleus part (LHb)
Increase, as shown in left side IHC images and the right quantitatively figure.Engineer's scale, 200 μm.(H) in acute Xi Ze-zong and chronic stress
(CMS) β CaMKII levels increase in depression model.ALH and ANLH be by LH pressure rat group, but ALH) performance LH diseases
Shape, ANLH do not show LH symptoms.(I) Western blot are analysis shows that the third miaow of cLH rats physiological saline or antidepressants
β CaMKII are horizontal in reins membrane part after piperazine processing.Data are average value ± SEM.*P<0.05, * * P<0.01, * * * P<0.001 with
Control group is compared.N.S. indicate that difference is not notable.Other icons are identical.
Fig. 2 shows that the overexpression of β CaMKI (and non-alpha CaMKII) in mouse and rat causes Depressive behavior.(A) AAV is carried
The engineered schematic diagram for being used for being overexpressed control structure, β CaMKII, α CaMKII or kinase dead mutant β CaMKII of body.
ITR, inverted terminal repeat;Cytomegalovirus (CMV), cytomegalovirus promoter;Ubi:Ubiquitin promoter;2A:Allow
The viral 2A connections peptide of a variety of non pregnant women translations.(B) WT mouse or rat are used for the experimental paradigm of performance testing.(C) small
The bilateral AAV- β CaMKII virus injections diagrams of mouse LHb (use anti-GFP and core label Hoechst counterstain).Engineer's scale, 50 μM of
(D-I) animal depression model, mouse (D-G) and rat (H, I), shadow of the expression different virus construction to behavior in animal LHb
It rings.(F, G) compares being tested in forced swimming Plays dead time (F) or sucrose preference for LHb infection cell scores plotteds
(G).Data are standardized using injection of AAV control mice average value.* P < 0.05, * * P<0.01, * * * P<0.001 compares
It is compareed with AAV in not injecting WT#P < 0.05.
Fig. 3 shows the spike potential output of the overexpression enhancing LHb neuronal synapse activity sums of β CaMKII.(A) outside reins
Core pair record schematic diagram (left figure).Right figure:β CaMKII infect under transmission (top) and fluorescence (bottom) light microscope
LHb neurons pairing repairing (green arrow) and adjacent uninfection neuron (red arrow is pointed out).Engineer's scale, 10 μM of
(B) the control group LHb neurons or AAV- β CaMKII, AAV- α CaMKII detected under full cell pattern infects neuron
MEPSC trace examples.The cumulative distribution (left side) of phase and average frequency between (C, D) mEPSC, by AAV- β CaMKII (C) or AAV- α
CaMKII (D) infects the mEPSC amplitudes (right side) of neuron.A pair of of control neuron and adjacent virus infection god are represented per a line
Value through member.(E) the control group LHb neurons or AAV- β CaMKII, AAV- α CaMKII detected under full cell pattern infects
The spontaneous discharge spike potential trace example of neuron.(F, G) infects nerve by AAV- β CaMKII (F) or AAV- α CaMKII (G)
The average frequency of spontaneous discharges of member.
Fig. 4 shows that β CaMKII knock out the depression phenotype that can give treatment to cLH rats and reduce LHb neuronal synapses in LHb
Activity.(A) engineering modification is used for being overexpressed the AAV carrier schematic diagrames of the RNAi of β CaMKII.H1:People's H1 promoters.(B) β is used
CaMKII RNAi constructions specific knockdown β CaMKII rather than α CaMKII.The pSUPER- β CaMKII- in 293tn cells
RNAi constructions be with AAV- β CaMKII or AAV- α CaMKII plasmid co-transfections, and first express before western analyses 48 small
When.It is left:Represent western blot.It is right:Knock out effect quantitatively.(C) experimental paradigm of virus infection cLH rat behaviors test.
(D-E) after cLH rat LHs b expression AAV- β RNAi and AAV- β K43R in forced swimming test (D) and Xi Ze-zong test (E, F)
Behavioral implications.(F) per class animal percentage.LH:≤ 5 bars oppress Xi Ze-zong rat.NLH:>=10 bars oppress non-acquistion without
Help rat.(G) subviral infection sub-region characterization.Upper figure:AAV- β RNAi viruses infect outside habenular nucleus in cLH rat brain slices
(LHb-L) and medial habenular nucleus (LHb-m) subregion legend.Engineer's scale, 10010 μM.Figure below:Compare cLH rat LHs b-l and LHb-m
The behavior response in Xi Ze-zong experiment that infection rate is drawn.(H) cLH rats AAV- β RNAi infect LHb neurons mEPSCs hairs
It is raw to change.Upper figure:MEPSC trace examples.By phase and average frequency iterated integral between the mEPSC of AAV- β RNAi infection LHb neurons
Cloth (lower-left), mEPSC amplitudes (bottom right).*P<0.05, * * P<0.01, * * * P<0.001 compares with cLH/AAV-
Fig. 5 shows that the cynapse for blocking GluR1-type ampa receptors can subtract in conjunction with (downstream molecules of a β CaMKII)
Light depression.(A, B) Western blot analysis shows that the GluR1 of cLH rat habenular nucleus protein extract membrane parts expression
Increase (A), is decreased obviously (B) after the processing of antidepressants imipramine.(C) the common table of AAV- β CaMKII-2A-GluR1Ct viruses is used
The immunohistochemistry signal of CaMKII and GluR1 in LHb is enhanced up to β CaMKII and GluR1Ct.It is right:IHC signal quantizations.
Engineer's scale, β CaMKII and GluR1Ct coexpressions are strong caused by having blocked β CaMKII to be overexpressed in 100 μM of (D, E) bilaterals LHb
Compel swimming test (D) and anhedonia (E) phenotype.(F) model illustrates:In normal state, LHb has VTA and DRN opposite
Weaker inhibition.The expression of the β CaMKII caused by depressive state, pressure raises, this causes the transport of GluR1 films to increase, and increases
LHb neuronal synapses efficiency and spike potential is added to export.Therefore, LHb is enhanced for the inhibition of VTA and DRN, and then leads to pleasant sensation
Shortage and behavioral despair.
Fig. 6 shows that proteomics data is analyzed.(A) data statistics flow chart (B) standardized data distribution (C) is
This experimental technique is verified, a sample is divided into two same sections and is run twice on mass spectrograph.Experiment weight twice
Complex data is compared to each other, and is shown highly relevant.
Fig. 7 shows that the candidate albumen expression by proteomics screening and identification eight raises (A), under four
It adjusts (B).It is worth noting that, most up-regulated expression albumen are molecule abundant in neuron, overwhelming majority expression is lowered
Albumen is the catalytic molecular for participating in basic metabolism function.
Fig. 8 shows the qRT-PCR verification results of expression up-regulation candidate albumen.*p<0.05, * * p<0.01 with compare
Group is compared
Fig. 9 shows the measurement result of CamKII families the other three member.(A, B) western engram analysis shows cLH
The variation of rat habenular nucleus (A) or α-, δ-and the γ-CaMKII in hippocampus (B) membrane part.
Figure 10 shows the result of the overexpression level estimation of Unilateral injection virus formulation object.(A) via these three viruses
The coronal noisy slice schematic diagram of mouse of Unilateral injection.Top panel:With anti-GFP (green) dyeing or direct visualizztion tdTomato
The brain section of (red), the brain section of Hoechst (blue) counterstain.It is left:Non-injection side.It is right:Injection side.D3V:Carry on the back third
Room.Bottom panel:The adjacent brain section of same mouse is dyed with anti-CamKII antibody, for the quantification in B figures.(B) it notes
It is horizontal to penetrate overexpression representated by the signal intensity ratio of the CaMKII of side and non-injection side.n=5for AAV-βCaMKII-2A-GFP,
N=4forAAV- α CaMKII-2A-tdTomato and AAV- β CaMKII-K43R-2A-GFP.
Figure 11 shows the front and back region where the most of expressing virals of mouse LHb virus target area schematic diagram (A).
Left figure is to come from the brain section schematic diagram of injection of AAV-β CaMKII virus mouse.Right figure is to adapt from Paxinos&
The correspondence principle figure of Franklin2004 atlas.
Figure 12 shows the open field experimental result of injection different virus mouse.(A) total displacement distance.(B) open field is real
Test middle center dwell time.
Figure 13 shows heterogeneity mEPSC response diagrams in LHb.(A) mEPSC is recorded in LHb differences subregion.Each point generation
The record of one neuron of table.MEPSC response frequencies are marked by color.(B) each point represents a pair of nerve of the regional record
Member.The value of each pair of neuron mEPSC frequency has all marked.(C) a neuron comparison is another in the pairs of neuron that figure B is recorded
The mEPSC frequencies of one neuron.It is worth noting that, although position is different, the neuron from same a pair shows height
Identical mEPSC frequencies.
Figure 14 shows the expression of habenular nucleus protein lysates whole or membrane part GluR1.(A) cLH rats are shown
The western engram analysis schematic diagrames changed with the total component of habenular nucleus or membrane part GluR1 levels of control rats.(B)GluR1
The quantification of level variation.
Specific implementation mode
The present inventor after extensive and in-depth study, is surprised to find that β CaMKII are that one of depression is extremely closed for the first time
Important regulatory factor combines the means such as molecule, behavior and electro physiology, it is determined that β CaMKII are to lead to habenular nucleus overacfivity
With the key molecule of behavior depression, the present invention is completed on this basis.
Specifically, habenular nucleus is overexpressed β CaMKII (and non-alpha CaMKII) and prominent transmission effect can not only be remarkably reinforced on the outside
The action potential of rate and outside Habenular Neurons exports, and can induce anhedonia and the core depression of behavioral despair
Shape.Habenular nucleus lowers the expression of β CaMKII on the outside, reduces its kinase activity or blocks its downstream molecules GluR1
The depressed phenotype of animal can then be reversed.The above result shows that β CaMKII are to adjust LHb neurons in the pathology of depression to occur
In the key molecule that functions.
Definition
As used herein, term CaMKII refers to cam kinase II (CaM kinase II).
As used herein, term " β CaMKII inhibitor " and " β CaMKII antagonists " are used interchangeably, and all refer to press down
The expression or protein active and prevention of system and/or antagonism β CaMKII or the substance for checking β CaMKII functions.
As used herein, term mEPSCs refers to electric current after miniature excitability protrudes.
As used herein, AMPAR, alpha-amido -3- hydroxy-5-methyl base -4- isoxazoles propionic acid (α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid (AMPA)) receptor
Method
A kind of method the present invention provides screening for preventing and/or treating the potential substance of depression, including step:
(1) tester to be screened is applied to animal models of depression, wherein the β in the animal models of depression
CaMKII is high expression;With
(2) related symptoms and/or index of the depression in the animal models of depression are observed, and are carried out with control group
Compare;
Wherein, the related symptoms of depression are significantly improved in the animal models of depression, then it represents that the tester is
It can be used for preventing and/or treat the potential substance of depression.
In addition, the animal model is non-human mammal, such as rodent, rabbit, Primate.
In addition, in step (2), pass through Animal Behavior Science Germicidal efficacy depressive symptom.The Animal Behavior Science experiment packet
It includes:Forced swim test, the experiment of sucrose preference, open field experiment.The index includes:Expression, the β of β CaMKII
The activity level of CaMKII.
Method the present invention also provides another screening for preventing and/or treating the potential substance of depression, including step
Suddenly:
(1) in test group, tester to be detected is added into vitro detection system;With
(2) detect the expression and/or activity of β CaMKII in the vitro detection system of the test group, and with feminine gender
Control group is compared;
Wherein, if compared with adding negative control group, the expression of β CaMKII is remarkably decreased in test group, and/
Or the activity of β CaMKII is remarkably decreased, then it represents that the tester is the potential substance for preventing and/or treating depression.It is described
Vitro detection system include cell system;Preferably neuronal cell system.
In addition, described is remarkably decreased finger, and compared with negative control, the expression or activity of β CaMKII in test group
It is the 5-90% of negative control group, preferably 10-60%, more preferably 20-50%.The step (2) further includes and positive controls
It is compared.
In addition, the method further includes following one or more steps:
To the potential substance that previous step filters out, its influence to the membrane part of GluR1 is further tested;
Animal model is applied to the potential substance that previous step filters out, observes its influence to symptoms of depression.
When testing its influence to the membrane part of GluR1, if compared with negative control group (or blank control group), add
Enter or reduced using GluR1 contents in the test group of the tester, then it represents that the tester is to prevent and/or treat depression
Potential substance.The GluR1 contents are the GluR1 contents on neuronal cell film.
Using
Prevent present invention could apply to depression and/or treat, the screening and preparation of drug can also be applied to.
Present invention will be further explained below with reference to specific examples.It should be understood that these embodiments are merely to illustrate the present invention
Rather than it limits the scope of the invention.In the following examples, the experimental methods for specific conditions are not specified, usually according to conventional strip
Part, such as Sambrook et al., molecular cloning:Laboratory manual (New York:Cold Spring Harbor
Laboratory Press, 1989) condition described in, or according to the normal condition proposed by manufacturer.Unless otherwise stated, no
Then percentage and number are weight percent and parts by weight.
Versatile material and method
Animal material
Male CHL diseases rat (4-7 week old) and Sprague Dawley rats of the same age.CHL rat feedings are as previously described
(1).Two/cage of rat, 12 hours light and shade periods (7am-7pm has light).Grow up (10-14 week old) C57BL/6 mouse by with
In performance testing:4/cage, 12 hours light and shade periods (5am-5pm has light).Rat and mouse can freely absorb stable
Water and food, all zooperies are by Chinese Academy of Sciences's Neuroscience Research institute's animal protection and use the approval of the committee.
Protein science
Proteome analysis are carried out to three groups of brain samples, every group include wild type SD rat controls and congenital acquistion without
(cHL) rat is helped, wherein congenital Xi Ze-zong rat all shows depressed row in Xi Ze-zong experiment and forced swim test
For.Brain is removed after isoflurane anesthesia, stiff band tissue, liquid nitrogen frozen are removed in rapid dissection.The reins tissue and warp of different samples15N
Mark (rat15In two generation of N feedings, makes atom be enriched with15N is separately added into precooling homogenate buffer up to rat whole brain tissue 95%)
(320mM sucrose,4mM HEPES pH7.4,1mM MgCl2With 0.5mM CaCl2,5mM NaF,1mM Na3VO4,EDTA-
Free, Protease Inhibitor cocktail tablets (Roche)), homogenate is made with glass homogenizer.With
Bradford measure protein content (Bio-Rad), by each sample homogenate respectively and15The full brain homogenates of N press protein ratio (w/w) 1:1
Mixing.Mixture 800g, 4 DEG C of centrifugation 15min take supernatant, supernatant 1000g, 15min centrifuging and taking precipitation.Precipitation is cell membrane
Part, 100ug precipitations are dissolved in homogenate buffer, and (MudPIT) (3) are analyzed with multidimensional protein identification techniques.For each
Albumen is estimated in peptide level14N/15Then the ratio of N seeks the average value of protein level.The ratio of thousands of albumen is asked
Log is converted into normal distribution, and normalization is so that intermediate value is 0.After normal state, the value of CHL divided by the value of control are exactly this
Situation of change of a albumen under depression.It is exactly the notable of each albumen that mean ratio after normal state, which subtracts 2 times of standard deviations,
Value.Variation >=50% and saliency value>0 albumen is as candidate, progress next step verification.The change after log is taken to each albumen
Change multiple and carry out Student's t-test, p value is shown in Table 1.
Virus formulation
AAV- β CaMKII-2A-EGFP, AAV- α CaMKII-2A-tdTomato are designed and build by standard method,
AAV- β CaMKII-K43R-2A-EGFP, AAV- β CaMKII-2A-Glu-R1Ct, AAV-GFP-CRE and AAV-GFP plasmids.β
CaMKII and α CaMKII full-length cDNAs are obtained from SD rat cdnas library.2A signal peptide sequences are from plenti-2A-EGFP matter
Infer in grain and obtain, AAV frame sequences are obtained by AAV-GFP-CRE plasmids (Lisa Monteggia give) clone.For
AAV- β CaMKII-2A-EGFP plasmids,
1) β CaMKII sequences are first added on plenti-Ubiquitin-2A-EGFP plasmids, obtain Ubiquitin- β
CaMKII-2A-EGFP plasmids, then AAV skeletons are introduced by BglII and XhoI restriction enzyme sites.
2) α CaMKII are cloned by BamH1 and Xba1 restriction enzyme sites on pLenti-2A-tdTomato carriers, and PCR expands
Increase CaMKII-2A-tdTomato sections of α on lenti carriers, AAV carriers are then cloned by Xbal1 and BsrG1 restriction endonucleases
On.
3) AAV- β CaMKII-K43R-2A-EGFP plasmids, β CaMKII-K43R segments pass through XbaL1 and EcoR1 digestions position
Point is cloned on AAV-2A-EGFP.
4) AAV- β CaMKII-2A-EGFP-GluR1Ct plasmids are expanded from pSindbis-EGFP-GluR1Ct plasmids
To EGFP-GluR1Ct segments, it is connect with AAV- β CaMKII-2A.
5) the bob folder oligonucleotide sequences (shRNAi) of β CaMKII are 5'-GAGTAT GCAGCTAA GATCA-3',
AAV- β CaMKII-RNAi are synthesized (shanghai, china) by Neuron Biotech companies.
These constructions are generated with AAV2 methods noted earlier.
In short, by an AAV carrier and two assistant carriers (pXX680 and pXX2), it is thin that it is transfected into HEK293TN together
Born of the same parents.Two days after transfection, with heparin-agarose post from cell pyrolysis liquid purified virus, and hyperconcetration obtains final volume.AAV2's
Helper plasmid pXX680 and pXX2 is bought from University of North Carolina.With the virus sense of 10 times of gradient dilutions
Contaminate HEK293TN raji cell assay Raji virus titers.
Anti depressant therapy
CLH rats pass through continuous 14 days injection imipramine (10mg/kg, sigma) progress anti depressant therapies.Divide after injection
Analyse performance testing.
Stereotactic injection and histology
When to mouse injecting virus, after intraperitoneal injection of ketamine (100mg/kg weight) and Xylazine (8mg/kg) anesthesia,
It is placed on stereotaxic frame (Stoelting instruments).All mouse of operation consent are 2 weeks or more gregarious.By 0.8-1ul
Viral (~1012 infectious units/ml) bilaterals of AAV for purifying concentration are injected into the positions LHb (the anterior fontanelle coordinate bit of every mouse
It sets:Outside (ML) in side (AP) before and after -1.32mm, ± 1.04mm, -2.48mm carry on the back veutro (DV), 14 ° of angles of coronal-plane center line), make
It is slowly injected into (~100-150nl/min) with glass microelectrode, 5min injection electrodes are slowly recalled after the completion of infusion.
To rat injecting virus, 10% chloraldurate of intraperitoneal injection (4ml/kg weight) is anaesthetized, the positions LHb (SD rats 4 weeks
Age, the AP-3.0mm from anterior fontanelle door, ML ± 0.7mm, the DV-4.4mm from anterior fontanelle door;4 week old of CHL rats, the AP- from anterior fontanelle door
3.0mm, ML ± 0.7mm, the DV-4.45mm from anterior fontanelle door;6 week old of CHL rats, the AP-3.3mm from anterior fontanelle door, ML ±
0.7mm, the DV-4.7mm from anterior fontanelle door) injection 1-1.5ul AAV viruses, be found that faint label effect on microelectrode beam.
Postoperative at least 7 days, carry out behavioral experiment or electro physiology experiment.Injection position is checked after behavioral experiment, is only used correct
Those of injection animal data.The rat of AAV- α CaMKII-tdTomato or the brain section of mouse have been injected in fluorescence microscopy
It is checked under mirror, other viruses that GFP is marked check GFP albumen before micrography with antibody.The reins area of each brain is cut
Continuously be sliced at 6 groups (slice of mouse 30um, every group 6;Rat 40um slices, every group of 8-9 piece).All slices are being pacified
Hoechst counterstain is used before being attached to fixinig plate.Calculate the infection rate in reins area.Infection rate counting is by using ImageJ one
It is carried out in the vertical brain section of group, total neural number in an area is that the NeuN in one group of slice with two control groups believes
It number is averaged.It is exactly infection rate with infection cell number divided by total neuron number.
Immunohistochemistry and immunoblotting
Perfusion:10% chloraldurate deep anaesthesia of rat or mouse with phosphate buffer (PBS) and contains 4% poly first
The phosphate of aldehyde (w/v) carries out cardiac perfusion.Brain fixing process after same 4% paraformaldehyde solution is stayed overnight, is then immersed in
In 30% sucrose (PBS) solution 1 day (mouse) or 3 days (rat).The brain of frost uses sliding microtome on coronal-plane
(CM1950, Leica) is cut into 30um (mouse) or 40um (rat) slices.Slice is immersed in PBS and refrigerates to be used after for 4 DEG C.
Antibody is rabbit-anti CaKMII (1:300, Epitomics) rabbit-anti GluR1 (1:300, Chemicon), the anti-NeuN antibody of mouse
(1:1000, Chemicon), rabbit-anti GFP antibody (1:1000, Invitrogen), the anti-GFP antibody of chicken (1:
1000, ABCAM), Alexa Fluor488 goat anti-rabbit iggs, Alexa Fluor488 sheep anti-chicken IgGs, Alexa Fluor594 sheep
Anti- mouse IgG (all1:1000, Invitrogen), the goat anti-rabbit igg of biotin labeling, the sheep anti-mouse igg of biotin labeling
(all1:250, Vector laboratories), Cy3- is coupled Streptavidin, and Cy2- is coupled Streptavidin (all1:
1000,Jackson ImmunoResearch).Specifically for the coloring of CaKMII and GluR1, we use three steps and put
Big operation:Slice uses CaKMII antibody or GluR1 antibody, the secondary antibody of biotin labeling, Cy3 or Cy2 coupling strepto- parents successively
It is incubated with element.All slices are finally incubated with Hoechst.Fluorescence imaging is using Olympus Fluoview FV1000 copolymerization
Focusing microscope (10X, 20X object lens) and Olympus MVX10microscope (MV PLAPO2XC object lens).Image analysis software
For Image-Pro Plus and ImageJ.The fluorescence intensity of CaKMII and GluR1 is quantitative:At 20X LHb is captured under identical setting
It infects side and is uninfected by side Confocal Images, and further analyzed by Image-Pro Plus.The regional value of Hoechst signals
Divided by the integrated optical density (IOD) of IHC signals obtains fluorescence intensity.Compare the fluorescence of virus the injection side and unimplanted side of LHb
Intensity obtains overexpression level.
Immunoblotting:The processing for handling spectrum analysis therewith of reins or hippocampal tissue is identical.10%PAGE glue SDS electrophoresis, often swims
Road applied sample amount 5-8ug albumen, revolving die do western traces, and antibody is anti-β CaMKII (1:4000,invitrogen),
anti-αCaMKII(1:2000,millipore),anti-γCaMKII(1:1000,PTG),anti-δCaMKII(1:500,
Santa Cruz) and anti-tubulin (1:10000,Bio-Rad).Use highly sensitive ECL reagents (GE
Helthcare)。
Slice prepares
After SD rats (after birth 40-50 days) are anaesthetized with isoflurane, perfusion 20ml precooling dissection buffer solutions (25.0mM
NaHCO3,1.25mM NaH2PO4,2.5mM KCl,0.5mM CaCl2,7.0mM MgCl2,25.0mM glucose,110.0mM
Choline chloride, 11.6mM ascorbic acid and 3.1mM pyruvic acid, gassed with95%O2With
5%CO2), fast anatomical brain after broken end, coronal reins uses vibratome (DSK II) in the freezing dissection buffer solution of oxidation
It is cut into 350 μm of slices.Reins is sliced in oxygen containing ACFS solution (118mM NaCl, 2.5mM KCl, 26mM NaHCO3,1mM
NaH2PO4,10mM glucose,1.3mM MgCl2With 2.5mM CaCl2,gassed with95%O2And 5%CO2) in restore two
Hour, it is transferred in the slot of the oxygen containing ACFS solution of sustainable supply.
Electro physiology
27 ± 1 DEG C of outside reins neuron patch-clamp experimental temperature, uses Multiclamp700B amplifiers (Molecular
Devices) and it is equipped with the Olympus Optical microscope of infrared differential interference comparison.Electrode resistance is 3-4M Ω.For mEPSC
It records, in the ACSF solution existing for TTX (1 μM) and picrotoxin (100 μM), clamps neuron at -60mv.Intracellular
Solution includes CsMeSO3115mM,CsCl20mM,HEPES10mM,MgCl22.5mM,Na2-ATP4mM,Na-GTP0.4mM,Na-
phosphocreatine10mM,EGTA0.6mM.Data are by Digidata1322A (Molecular Devices) in 2kHz
It filters and in 10kHz random samplings.MEPSC analyses use Mini Analysis Program (Synaptosoft), threshold value width
Degree is 5PA.In order to measure spontaneous discharge rate, neuron is connected into cell attachment device, there are picrotoxin
(picrotoxin) in ACSF solution.Electrode resistance 6-7M Ω, solution is NaCl118mM, HEPES10mM in electrode.Each
50 scanning of cell record, every time scanning continue 7s, and data are analyzed by pClamp10 softwares.
Behavioral experiment
All behavioral experiments are all to carry out (mouse 18 in the circadian rhythm phase at night:00–23:00);Rat 19:00-24:
00).
Xi Ze-zong experimental paradigm carries out (5) according to the specification of optimization noted earlier.Experiment is to brood cLH or wild
Type SD rats carry out.Normal form includes two parts." training part " is included in stimulation room (coulbourn instruments), and 120 times are not
Evitable, the uncontrolled volas 0.8mA electro photoluminescence is more than 40 minutes, and random stimulus duration and range are from 5 seconds to 15 second
It is spaced stimulation time, total stimulus duration is 20 minutes." part of detecting " training carries out after 24 hours, and Xi Ze-zong phenotype is
Task is oppressed by a bar to be assessed, one illumination indicating arm of period is placed into stimulation room.This part can including 15 times
The 0.8mA intensity electro photoluminescence of escape and 24s trial intervals.Stimulation continue for 60 seconds every time, but can be oppressed and terminate by bar.It is more than
Unsuccessfully it is defined as " Xi Ze-zong " (LH) for 10 times;It is unsuccessfully less than 5 times " non-Xi Ze-zong " (NLH).
In forced swim test, rat or mouse are placed on (23-25 DEG C of the water temperatures of 6min in water vat;For mouse, water vat
Diameter 12cm, height 25cm;For rat, water vat a diameter of 20cm, height 40cm.The depth of water is that animal uses it in order to prevent
Hind leg bottom out).Rat swims there are one additional 15min in the previous day and guides.Animal behavior is by from side video record.
Each animal is in the dead time for testing last 4min by not knowing that the observer of animal processing mode calculates.Motionless definition is floating
It is dynamic or stationary, it means that there is no any other movements for the action exposed the surface in addition to holding head.
In the test of sucrose preference, first mouse is individually disposed 1 week, then gets used to two bottle of 1% sucrose feeding 3 days, then two
Bottle water feeding one day.Then mouse stops water inlet 24 hours, is then exposed to 2h before two bottled full 1% sucrose or water.Two bottles after 1h
Location swap.The total flow of each fluid is measured, it is molten that the sucrose solution consumption that sucrose preference is defined in 2h tests accounts for sucrose
The ratio of liquid and water total flow.
Open-field test is carried out after every other performance testing.In a bright room, rat or small
Mouse is placed on the center of a plastic casing (for mouse:40cm×40cm×40.5cm;For rat 80cm × 80cm ×
40cm) 6min, during test, animal behavior is videoed, and then uses EthoVision Pro video frequency following systems and software
(Noldus) it analyzes.The total distance of mouse movement is calculated using software and the box center the time spent in.
Statistical analysis
All data are all with average value ± SEM.For all behavioral datas, using two-tailed Student's
t-tests.The western blot data that AAV- β CaMKII-2A-EGFP and AAV- α CaMKII-2A-tdTomato are overexpressed
And electric physiological data, using double tail paired t-tests.The electro physiology detection data of AAV- β CaMKIIRNAi, using paired
Wilcoxon-tests。
Embodiment 1
As a result as shown in Figure 1A the cultivation phenotype Xi Zezong cLH rats of selectivity show as from can escape vola
Under electric shock number is escaped to significantly reduce, this performance can by chronic antidepressant medicine treat reverse (imipramine, ip, 10mg/kg, 14
It) (Figure 1A).CLH rats also show as immobility in forced swimming test and increase (Figure 1A).
Embodiment 2
The bilateral habenular nucleus tissue of cLH and wild type control group rat are detached, quantitative proteomics analysis is carried out.
Extraction protein is used for15The quantitative proteomics analysis (Figure 1B) of N stable isotope labelings.In order to reduce sample
Complexity, we be extracted memebrane protein component and carried out three times independent sample analysis (Fig. 6, Fig. 7, Fig. 8, table 1).Study table
β CaMKII expression significantly up-regulation (being 1.9 times of wild type control, P=0.01, Fig. 1 C) in bright cLH rats habenular nucleus.To CaMKII
Other hypotypes of family are also detected:Expressions of the α CaMKII in different samples differs greatly, but still observes
Up-regulation trend;δ CaMKII are remained unchanged;γ CaMKII show 1.3 times of increase (P=0.0013) (Fig. 9).Due to brain
Middle β CaMKII ratio γ CaMKII are more rich, we study for the hypotype of this CaMKII.Pass through western blot point
Analyse secondary verification, it is determined that in cLH habenular nucleus sample film protein extracts β CaMKII compared with control group have 0.86 times increase (P=
0.003) (Fig. 1 D), but then without increasing (P=0.33, Fig. 1 E) in cLH hippocampus samples.Real-time quantitative PCR detection shows β
The mRNA level in-site of CaMKII shows 0.37 times of increase (P=0.04) (Fig. 1 F), this shows that transcriptional control at least partly results in
The variation of protein level.The reins staining brain sections of immunohistochemistry are shown:The increase of CaMKII protein expression levels is happened at outside
Reins (Fig. 1 G).
Table 1
Embodiment 3
β CaMKII expressions are further had detected in other two depression model, one is acute Xi Ze-zong,
It is induced and is generated by multiple inevitable and uncontrollable foot shock;Another kind is chronic mild stress, when passing through long
Between be exposed to unpredictable slight stress-induced and generate.The expression of β CaMKII is also apparent under both Stress models
Increase (Fig. 1 H), shows that the variation of the expression of β CaMKII is not limited to a kind of induction normal form of depression.In addition, imipramine
Anti depressant therapy (can reverse cLH rat depression phenotypes (Figure 1A)), lead to the aobvious of β CaMKII protein expressions in cLH rat reins
It writes and lowers (Fig. 1 I).The result shows that in the animal of depressive state and anti depressant therapy, β CaMKII show two-way level
Variation.
Embodiment 4
Viral vectors (adeno-associated virus (AAV)) is built, scale is crossed in wild-type mice and Lateral Habenular Nucleus (LHb)
Up to β-or α-CamKII, and test the effect (Fig. 2A-C) in various depression models.Because LHb neurons are almost paddy ammonia
Sour energy, so we drive extensive and efficient gene expression using ubiquitin promoter.In order to estimate overexpression level, I
Will express CaMKII virus injection habenular nucleus side.After injection 14 days, compared to non-injection side, injection side CaMKII water
It is flat as follows:AAV- β CaMKII are 4.4 ± 0.6 times, and AAV- α CaMKII are 4.6 ± 0.9 times (Figure 10).We are again by virus injection
Depressive behavior test (Fig. 2 B, 2C, Figure 11) is carried out to the both sides LHb and after expressing 10 days.
Embodiment 5
Viral vectors (adeno-associated virus (AAV)) is built, scale is crossed in wild-type mice and Lateral Habenular Nucleus (LHb)
Up to β-or α-CamKII.Compared with injecting control group, the overexpression of β CaMKII in the mouse LHb for not living through stress stimulation
Mouse dead time (P=0.003) in high-amplitude wave swimming test can be caused to dramatically increase, occur being ignorant of the shorter latencies of action
(P=0.048).Open-field test shows that the spontaneous activity of these mouse without significant difference (Figure 12), shows that immobility less may be used
Can be caused by movement defect.In addition, β CaMKII overexpressions can also cause anhedonia, source of evidence molten to sucrose in mouse
The preference of liquid significantly reduces (P=0.01, Fig. 2 E).
Embodiment 6
In order to estimate to generate the minimum infection rate needed for depressive type, this research increases by one group of Bilateral injections 1:10 is diluted
The mouse of AAV- β CaMKII viruses.Different from general injection group (infection rate is 38 ± 3%), this dilution injection group (sense
Dye rate is 5 ± 0.6%) depressed phenotype (Fig. 2 F, 2G) is not shown.Therefore, depression severity and outside habenular nucleus β
CaMKII infection rates are relevant.By contrast with β CaMKII, the overexpression of α CaMKII or GFP-Cre as a contrast,
Under similar infection rate (β CaMKII36 ± 2.5%, GFP-CRE36 ± 3%), without result in similar depressed effect (Fig. 2 D-E).
Embodiment 7
CaMKII molecules are used as kinases and structure stand albumen simultaneously in cynapse, and research kinase activity is to β CaMKII work(
Can importance, carrier construction AAV- β CaMKII-K43R-2A-EGFP, in rat by watchband β K43R in habenular nucleus.β CaMKII's
One without kinase activity mutant, β K43R (being contained in a simple point mutation on lys43arg) though be overexpressed to β CaMKII
Wild type similar level when (4.6 ± 0.5 times, infection rate be 40 ± 3%, Figure 10), do not cause depression phenotype (Fig. 2 D,
2E), this shows that the kinase function of β CaMKII is necessary for generating depression.In addition, the β CaMKII in Lateral Habenular Nucleus
Overexpression equally dramatically increase forced swimming test in immobility (P=0.02) and reduction flight behavior, be embodied in acquistion
Property helpless experiment in terminate the number of electric shock by pressing lever and reduce (Fig. 2 H, 2I).These results indicate that pressing down in multiple animal
In strongly fragrant model (including rat and mouse), the expression of β CaMKII (rather than α CaMKII) rises in outside habenular nucleus (LHb),
It is enough to lead to very strong depressive symptom.
Embodiment 8
Change the activity of LHb neurons and the cell mechanism of function to inquire into β CaMKII and be overexpressed, we are to wild type
The LHb neurons of virus infection and adjacent uninfection carry out pairs of Whole-cell recording (figure in rat brain slice
3A).First, for the LHb neuronal synapse characteristics of detection, we measure miniature excitatory postsynaptic currents (mEPSCs) (
The picrotoxin of tetraodotoxin for preventing action potential and the synaptic currents for blocking GABAA mediations
(picrotoxin) in the presence of), this electric current is the alpha-amido -3- hydroxy-5-methyl base -4- isoxazole propionic acid by glutamate receptor
(α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)) hypotype is mediated and body
The single synaptic response being recorded on neuron is showed.
In the brain section being uninfected by, adjacent outside Habenular Neurons to showing the frequency of the similar mEPSC of height,
Although subregions different LHb exists heterogeneous (Figure 13).In the neuron infected by AAV- β CaMKII, mEPSC frequencies are big
It is big to increase (being 351 ± 51%, P=0.0004 of adjacent control group), mEPSC amplitudes it is same (be the 130 ± 10% of control group,
P=0.003, Fig. 3 B, 3C).By contrast, AAV- α CaMKII infection can cause the faint decline of mEPSC frequencies (to be control group
81 ± 9%, P=0.047), mEPSC amplitudes are then without variation (being 87 ± 5%, P=0.12 of control group, Fig. 3 B, 3D).
Embodiment 9
In order to detect the output of these LHb neurons, we use the spontaneous of the method neuron of cell attachment formula record
Granting rate.The neuron granting rate of AAV- β CaMKII infection is 3 times of (P=0.0005, figures of the neuron of periphery uninfection
3E, 3F), and this variation (P=0.1, Fig. 3 E, 3G) is not detected then in the neuron of AAV- α CaMKII infection.These knots
Fruit shows increase significantly the cynapse efficiency of up-regulation LHb neurons and spike potential output of β CaMKII expressions, this is very big
The neuron variation observed in the animal of depression is simulated in degree.
Embodiment 10
In order to determine that β CaMKII expressions are lowered in LHb or whether the function blocking of β CaMKII can reverse depressed table
Type, we use RNA interference (RNAi) to reduce β CaMKII protein levels (Fig. 4 A) first.Previously have been reported that display specifically for β
The short hairpin RNA of CaMKII transcriptions can effectively reduce β CaMKII protein levels, without influence α CaMKII (35, Fig. 4 B).
Then this RNAi form of our the expression β CaMKII in AAV viral (AAV- β RNAi), and infected by Bilateral injections
CLH rat LHs b carries out targeted expression (Fig. 4 C).It is shown in the forced swimming test dead time by the cLH rats of AAV- β RNAi infection
It writes and reduces (P=0.0005), escape behavior (P=0.02, Fig. 4 D, 4E) is significantly increased in Xi Ze-zong test.Xi Ze-zong
Animal percentage (being defined as be below 5 times by bar) drop to 25% (Fig. 4) from 83.3%.
Embodiment 11
In order to exclude potential RNAi undershooting-effects, we further test one of β CaMKII without kinase activity type,
β K43R, it can block the function (33, Fig. 2A) of endogenous β CaMKII as a dominant invalid factor when being overexpressed.When
After AAV- β K43R viruses are injected into cLH rat LHs b, forced swimming test and Xi Ze-zong test in all detect with
Antidepressant effect (Fig. 4 D-4F) similar AAV- β RNAi.It is interesting that down to the AAV- β RNAi of 17 ± 3% infection rates or 30 ±
The AAV- β K43R of 3% infection rate are enough to realize these strong antidepressant effects, prompt LHb neural network redundancies small, and change
The activity of relatively small ratio LHb neurons is just enough to improve depression.
Embodiment 12
The further subregion of analysis infection LHb, the insides discovery LHb infection rate, rather than exterior portion, with improving depression
Effect is closely related, this result prompts may be more important (Fig. 4 G) to the improvement of Xi Zezong behavior on the inside of LHb.It is big in cLH
In mouse LHb brain pieces, significantly reduce (control group of adjacent uninfection by the neuron mEPSC frequencies of AAV- β RNAi infection
53.5 ± 15.3%, P=0.008, Fig. 4 H).In short, β CaMKII or blocking its effect these results indicate that knocking out, can obviously subtract
The symptom of light depression.
Embodiment 13
It has detected the level of the GluR1 in cLH rat LHs b, finds to be adjusted to (the 222 of control group on horizontal on GluR1 films
± 41.7%, P=0.006, Fig. 5 A), be significantly higher than total GluR1 the increased multiple of level (147 ± 19%, P of control group=
0.02, Figure 14).On the contrary, the expression in the cLH rat membrane components GluR1 of antidepressants imipramine processing declines (control
72 ± 8%, the P=0.003, Fig. 5 B of group).
Embodiment 14
In order to detect effects of the GluR1 in the adjusting of β CaMKII depression, we use AAV- β CaMKII-2A-
GluR1Ct viral vectors has been overexpressed a dominant factor of β CaMKII and GluR1, GluR1Ct, to hinder simultaneously
The cynapse of GluR1 is transported.Expression testing result based on Unilateral injection show β CaMKII show 3.8 times and
GluR1Ct is the overexpression (Fig. 5 C) of 3.7 times of Endogenous levels.When this viral bilateral is injected into wild-type mice
LHb (infection rate is 37 ± 2%), two groups of mouse are all acted normally (Fig. 5 D, 5E) in forced swimming and the test of sucrose preference.Cause
This, the coexpression of GluR1Ct prevents β CaMKII to be overexpressed caused depressed effect.These results indicate that AMPAR GluR1
The adjusting that cynapse is transmitted is the important downstream targets that β CaMKII show depressive symptom
All references mentioned in the present invention is incorporated herein by reference, independent just as each document
It is incorporated as with reference to such.In addition, it should also be understood that, after reading the above teachings of the present invention, those skilled in the art can
To be made various changes or modifications to the present invention, such equivalent forms equally fall within model defined by the application the appended claims
It encloses.
Claims (29)
1. a kind of purposes of β CaMKII inhibitor, which is characterized in that be used to prepare prevention and/or treat the drug of depression, institute
The inhibitor stated is selected from the group:
(i) RNA interfering or its precursor of interference β CaMKII expression;
(ii) the saltant type β CaMKII albumen or its coded sequence that kinase activity declines or loses;
(iii) inhibit the active inhibitor of β CaMKII;
(iv) competitive inhibitor of β CaMKII;
(v) antibody of anti-β CaMKII;
(vi) antagonist of β CaMKII regulation and control AMPAR GluR1 accesses is checked;
Also, the drug be targeting in the drug of outside habenular nucleus or the drug be applied to outside habenular nucleus region or
Near zone;The β CaMKII inhibitor selective depression β CaMKII, and to other CaMKII unrestraints/antagonisms.
2. purposes as described in claim 1, which is characterized in that the inhibitor is selected from the group:
(i) RNA interfering or its precursor of interference β CaMKII expression;
(iv) competitive inhibitor of β CaMKII;
(vi) antagonist of β CaMKII regulation and control AMPAR GluR1 accesses is checked.
3. purposes as described in claim 1, which is characterized in that the RNA interfering is β RNAi, such as SEQ ID NO.:1 institute
Show, 5'-GAGTATGCAGCTAAGATCA-3'.
4. purposes as described in claim 1, which is characterized in that the saltant type β CaMKII albumen is that β CaMKII albumen is aobvious
Property inactivation factor.
5. purposes as described in claim 1, which is characterized in that the component (vi) be AMPAR GluR1 dominant because
Son.
6. purposes as claimed in claim 5, which is characterized in that the component (vi) is GluR1Ct.
7. purposes as described in claim 1, which is characterized in that the inhibitor includes following form:It is polynucleotides, more
Peptide, expression vector, micromolecular compound, or combinations thereof.
8. purposes as claimed in claim 7, which is characterized in that the expression vector is selected from the group:Viral vectors.
9. purposes as described in claim 1, which is characterized in that the β CaMKII inhibitor, which is additionally operable to prepare, reduces outside
The drug of the drug of the neuron spike potential output of habenular nucleus and/or the synaptic efficacy of reduction outside habenular nucleus.
10. purposes as described in claim 1, which is characterized in that the drug includes:
Pharmaceutically acceptable carrier;With
Effective quantity active constituent, wherein the active constituent is the β CaMKII inhibitor.
11. purposes as claimed in claim 10, which is characterized in that the active constituent makees α CaMKII unrestraints/antagonism
With.
12. purposes as claimed in claim 10, which is characterized in that the active constituent makees δ CaMKII unrestraints/antagonism
With.
13. purposes as claimed in claim 10, which is characterized in that the active constituent is to γ CaMKII unrestraints/antagonism
Effect.
14. purposes as described in claim 1, it is characterised in that other described CaMKII include α CaMKII, γ
CaMKII and δ CaMKII.
15. purposes as claimed in claim 10, which is characterized in that the drug is oral preparation, injection or targeting system
Agent.
16. the purposes of a kind of β CaMKII albumen or its coded sequence and/or β CaMKII accelerating agents, which is characterized in that for making
Standby a reagent or composition, the reagent or composition are moved for building animal models of depression, and in the depression
In object model, β CaMKII are high expression in habenular nucleus on the outside, wherein the animal model is non-human mammal.
17. purposes as claimed in claim 16, which is characterized in that the high expression refers to >=150%, by mRNA level in-site or egg
White level meter.
18. purposes as claimed in claim 17, which is characterized in that the high expression refers to >=200%.
19. purposes as claimed in claim 17, which is characterized in that the upper limit of the high expression is 2000%.
20. purposes as claimed in claim 16, which is characterized in that the animal models of depression is for screening for preventing
And/or the animal model of the potential substance for the treatment of depression.
21. purposes as claimed in claim 16, which is characterized in that the non-human mammal is selected from the group:Rodent, spirit
Long animal, or combinations thereof.
22. purposes as claimed in claim 19, which is characterized in that the upper limit of the high expression is 1000%.
23. purposes as claimed in claim 22, which is characterized in that the upper limit of the high expression is 500%.
24. a kind of method of screening for preventing and/or treating the potential substance of depression, which is characterized in that including step:
(1) in test group, tester to be detected is added into vitro detection system;With
(2) expression and/or activity of β CaMKII in the vitro detection system of the test group, and and negative control are detected
Group is compared;
Wherein, if compared with adding negative control group, the expression of β CaMKII is remarkably decreased and/or β in test group
The activity of CaMKII is remarkably decreased, then it represents that the tester is prevention and/or treats the potential substance of depression, also, institute
The vitro detection system stated is outside Habenular Neurons system.
25. method as claimed in claim 24, which is characterized in that described is remarkably decreased finger, compared with negative control, test
The expression of β CaMKII or activity are the 5-90% of negative control group in group.
26. method as claimed in claim 25, which is characterized in that described is remarkably decreased finger, compared with negative control, test
The expression of β CaMKII or activity are the 10-60% of negative control group in group.
27. method as claimed in claim 26, which is characterized in that described is remarkably decreased finger, compared with negative control, test
The expression of β CaMKII or activity are the 20-50% of negative control group in group.
28. method as claimed in claim 24, which is characterized in that the step (2) further includes being carried out with positive controls
Compare.
29. method as claimed in claim 24, which is characterized in that the method further includes following one or more steps:
To the potential substance that previous step filters out, its influence to the membrane part of GluR1 is further tested;
When testing its influence to the membrane part of GluR1, if compared with negative control group, being added or applying the tester
Test group in GluR1 contents reduce, then it represents that the tester be prevent and/or treatment depression potential substance;
The GluR1 contents are the GluR1 contents on neuronal cell film.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310347938.6A CN104338135B (en) | 2013-08-09 | 2013-08-09 | The regulatory factor of depression and its application |
PCT/CN2014/084101 WO2015018375A1 (en) | 2013-08-09 | 2014-08-11 | Depression regulatory factor and applications thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310347938.6A CN104338135B (en) | 2013-08-09 | 2013-08-09 | The regulatory factor of depression and its application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104338135A CN104338135A (en) | 2015-02-11 |
CN104338135B true CN104338135B (en) | 2018-08-24 |
Family
ID=52460687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310347938.6A Active CN104338135B (en) | 2013-08-09 | 2013-08-09 | The regulatory factor of depression and its application |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104338135B (en) |
WO (1) | WO2015018375A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108853510B (en) * | 2017-05-09 | 2022-05-20 | 浙江大学 | Treatment and medicaments for depression with a combination of an NMDAR inhibitor and a T-type calcium channel inhibitor |
CN108853504B (en) * | 2017-05-09 | 2022-05-20 | 浙江大学 | Modulation and use of T-type calcium channel inhibitors for depression |
CN115006534B (en) | 2017-05-09 | 2023-11-21 | 浙江大学 | Use of potassium channel Kir4.1 inhibitors for treating depression and pharmaceutical compositions |
CN108853502B (en) * | 2017-05-09 | 2024-06-14 | 浙江大学 | Method and pharmaceutical composition for treating depression |
WO2019000145A1 (en) * | 2017-06-26 | 2019-01-03 | 深圳市博奥康生物科技有限公司 | Method for constructing recombinant cho cell highly expressing ampar |
EP3681489A4 (en) * | 2017-09-10 | 2021-05-26 | Carmel Haifa University Economic Corporation Ltd. | Methods for treating depression and major depresive disorder |
CN110082516A (en) * | 2019-05-08 | 2019-08-02 | 中国科学院深圳先进技术研究院 | A kind of brain cell information acquisition method of various dimensions and its application |
CN114305423B (en) * | 2022-02-08 | 2023-07-07 | 浙江浙大西投脑机智能科技有限公司 | Depression state indication determining device based on neuron spike signal |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2435586A4 (en) * | 2009-05-29 | 2012-12-26 | Genomind Llc | Methods for assessment and treatment of depression via utilization of single nucleotide polymorphisms analysis |
-
2013
- 2013-08-09 CN CN201310347938.6A patent/CN104338135B/en active Active
-
2014
- 2014-08-11 WO PCT/CN2014/084101 patent/WO2015018375A1/en active Application Filing
Non-Patent Citations (2)
Title |
---|
"7-Hydroxystaurosporine may have a therapeutic role in treatment-resistant depression by inhibition of calcium/calmodulin-dependent protein kinase II";Enzo Emanuele et al.;《Medical hypotheses》;20070228;第68卷(第1期);第236-237页 * |
"缰核介导P物质受体拮抗剂抗抑郁的分子机制研究";于蕾;《中国博士学位论文全文数据库(电子期刊)》;20100715(第7期);第73-76页 * |
Also Published As
Publication number | Publication date |
---|---|
WO2015018375A1 (en) | 2015-02-12 |
CN104338135A (en) | 2015-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104338135B (en) | The regulatory factor of depression and its application | |
Bao et al. | Long-range GABAergic inputs regulate neural stem cell quiescence and control adult hippocampal neurogenesis | |
Cheng et al. | HCN2 channels in cholinergic interneurons of nucleus accumbens shell regulate depressive behaviors | |
Hou et al. | Central control circuit for context-dependent micturition | |
Alberio et al. | A light-gated potassium channel for sustained neuronal inhibition | |
Guerrini et al. | Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum | |
Niederkofler et al. | Functional interplay between dopaminergic and serotonergic neuronal systems during development and adulthood | |
Ma et al. | Distinct subtypes of somatostatin-containing neocortical interneurons revealed in transgenic mice | |
Zhou et al. | Requirement of TORC1 for late-phase long-term potentiation in the hippocampus | |
Zhu et al. | Intermittent hypoxia promotes hippocampal neurogenesis and produces antidepressant-like effects in adult rats | |
Angata et al. | Sialyltransferase ST8Sia-II assembles a subset of polysialic acid that directs hippocampal axonal targeting and promotes fear behavior | |
Lu et al. | Maintenance of GABAergic activity by neuregulin 1-ErbB4 in amygdala for fear memory | |
Groisman et al. | Differential coupling of adult-born granule cells to parvalbumin and somatostatin interneurons | |
Blasiak et al. | Excitatory orexinergic innervation of rat nucleus incertus–Implications for ascending arousal, motivation and feeding control | |
Hansen III et al. | Senescent-induced dysregulation of cAMP/CREB signaling and correlations with cognitive decline | |
Vargas-Hurtado et al. | Differences in mitotic spindle architecture in mammalian neural stem cells influence mitotic accuracy during brain development | |
Maddaloni et al. | Serotonin depletion causes valproate-responsive manic-like condition and increased hippocampal neuroplasticity that are reversed by stress | |
Xie et al. | A brain-to-spinal sensorimotor loop for repetitive self-grooming | |
Yao et al. | Neuritin up-regulates Kv4. 2 α-subunit of potassium channel expression and affects neuronal excitability by regulating the calcium-calcineurin-NFATc4 signaling pathway | |
Wang et al. | Adenosine A 2A receptors in the olfactory bulb suppress rapid eye movement sleep in rodents | |
Zhuang et al. | The antidepressant-like effect of alarin is related to TrkB-mTOR signaling and synaptic plasticity | |
Gong et al. | Effects of the regulation of polysialyltransferase ST8SiaII on the invasiveness and metastasis of small cell lung cancer cells | |
Yang et al. | Inhibition of Nwd1 activity attenuates neuronal hyperexcitability and GluN2B phosphorylation in the hippocampus | |
Williams et al. | Cortical nNOS/NK1 receptor neurons are regulated by cholinergic projections from the basal forebrain | |
Yeh et al. | Knockdown of cyclin-dependent kinase 10 (cdk10) gene impairs neural progenitor survival via modulation of raf1a gene expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200521 Address after: 200031 No. 320, Yueyang Road, Shanghai, Xuhui District Patentee after: Center for excellence and innovation of brain science and intelligent technology, Chinese Academy of Sciences Address before: 200031 Yueyang Road, Shanghai, No. 319, No. Patentee before: SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES |
|
TR01 | Transfer of patent right |